logo-loader
viewIQ-AI Limited

IQ-AI soars as StoneChecker software gets US FDA sign-off

Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the regulator

IQ-AI Limited -

IQ-AI Ltd (LON:IQAI) said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.

Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the US Food & Drug Administration.

The company said it would issue an update outlining the scale of the opportunity along with its product roll-out plans in the next few days.

IQ-AI shares surged 41% to 6.65p on Friday morning.

-- Adds shares price --

Quick facts: IQ-AI Limited

Price: 4.85 GBX

LSE:IQAI
Market: LSE
Market Cap: £6.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FDA StoneChecker clearance a 'validation and tremendous leap...

IQ-AI Limited's (LON:IQAI) David Smith says the focus of their work on StoneChecker's moved into the commercial phase following FDA clearance for the product in the US. The software helps to identify the patients who would respond best to lithotripsy, which breaks up kidney stones using sound...

on 1/10/19

2 min read